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Background: Flow cytometry is the most commonly used technology to measure microvesicles (MVs). Despite
reported limitations of this technique, MV levels obtained using conventional flow cytometry have yielded
many clinically relevant findings, such as associations with disease severity and ability to predict clinical
outcomes. This study aims to determine if MV enumeration by flow cytometry correlates with a measurement
of their functional capacity, as this may explain how flow cytometry generates clinically relevant results.
Methods: One hundred samples from healthy individuals and patients with obstructive sleep apnoea were
analysed by conventional flow cytometry (FACSCalibur) and by three functional MV assays: Zymuphen
MP-activity in which data were given as phosphatidylserine equivalent, STA† Phospholipid Procoag Assay
expressed as clotting time and Endogenous Thrombin Potential (ETP) reflecting in vitro thrombin generation.
Correlations were determined by Spearman correlation.
Results: Absolute counts of lactadherin procoagulant MVs generated by flow cytometry weakly correlated
with the results obtained from the Zymuphen MP-activity (r0.5370, pB0.0001); correlated with ETP
(r0.7444, pB0.0001); negatively correlated with STA† Phospholipid Procoag Assay clotting time (0.7872,
pB0.0001), reflecting a positive correlation between clotting activity and flow cytometry. Levels of Annexin
V procoagulant and platelet-derived MVs were also associated with functional assays. Absolute counts of
MVs derived from other cell types were not correlated with the functional results.
Conclusions: Quantitative results of procoagulant and platelet-derived MVs from conventional flow cyto-
metry are associated with the functional capability of the MVs, as defined by three functional MV assays. Flow
cytometry is a valuable technique for the quantification of MVs from different cellular origins; however,
a combination of several analytical techniques may give the most comprehensive information on the role of
MVs in health and disease.
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T
he last few years have seen a steep increase in the
number of investigations of extracellular vesicles
within fundamental cell biology and in clinical
research. Developments in the size analysis, phenotyping
and absolute count determination of microvesicles (MVs)
have significantly furthered our understanding of their
biological roles in health and diseases. Despite technolo-
gical developments, the most commonly used method to
measure MVs remains conventional flow cytometry, which
is acknowledged to have several significant limitations.
The greatest limitation is that conventional flow
cytometry is unable to detect small MVs. Depending
on the flow cytometer, the lower limit of detection for
MVs was estimated to be 0.20.5 mm (13). This limit of
detection has been calculated using size-calibrated poly-
styrene beads; however, polystyrene beads have a differ-
ent refractive index to biological MVs and therefore these
estimates of flow cytometry resolution may have been
generous (4). The difference in refractive index between
biological vesicles and polystyrene beads suggests that

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flow cytometers set-up to gate on particles 0.51.0 mm
using calibrated beads might actually be selecting vesicles
in the range of 0.82.4 mm in size (5). Of note, silica beads
have a refractive index much closer to that of biological
MVs (6).
Technologies, such as nanoparticle tracking analysis
(NTA) and atomic force microscopy (AFM), have indi-
cated that the majority of extracellular vesicles are smaller
than 0.3 mm in diameter (7,8), suggesting that flow cyto-
metry is only capable of measuring the ‘tip of the iceberg’.
However, novel technologies may also be detecting some
non-vesicular events.
It is possible that smaller vesicles are measured by flow
cytometry, by a process known as swarm detection (6).
Due to the small size of the vesicles and the relatively
large flow cell, multiple vesicles may pass through the
flow cell and be detected at the same time. This would
allow for the detection of small-sized vesicles by flow
cytometry, but would give a false underestimation of the
absolute count coupled with an overestimation of their
size range. Nevertheless, it is still possible to determine
whether swarming is occurring during measurements
by performing serial dilution and linearity analysis of
samples (2).
New-generation flow cytometers have improved resolu-
tion of small vesicles, potentially down to 0.1 mm (1,9,10),
by increasing the light collection angle to facilitate im-
proved resolution. This alters the light collection on
scatter, allowing small particle-dedicated instruments to
have greater sensitivity. High sensitivity flow cytometry
has been found to give improved FSc resolution, lower
background noise and detects 820 times more MVs than
standard flow cytometry in patient samples. The ratio
of small to large MVs also varied according to clinical
status of the patient, suggesting that the size of MVs may
provide additional biological information (11). However,
new-generation flow cytometers are still not widely
available, particularly in clinical settings.
Despite all of the above mentioned limitations, many
studies with quantitative MV results generated using
only conventional flow cytometry have revealed clinically
relevant findings, such as associations with disease severity
and ability to predict clinical outcomes (1214). It is
possible that the ‘tip of the iceberg’ is representative of the
whole and a potential way to support this theory would
be to determine if the number of MVs measured by flow
cytometry is related to their functional capacity which by
definition will measure the entire vesicle population.
Several assays have been developed or adapted, to
measure the functional procoagulant capacity of MVs.
This study will compare three commercially available
functional MVs assays to each other and then with
absolute count results generated by flow cytometry, to
determine if the quantitative flow cytometry results can
be correlated with the functional capacity of MVs.
Methods
Samples
Fifty-three healthy control samples were obtained from
hospital staff and from a study investigating sleep and
psychomotor performance at altitude (only samples taken
at baseline were used). Subjects were eligible if they were
healthy, aged between 18 and 70 years. Subjects with a
body mass index (BMI) B18 or 30 kg/m2 (mean (SD)
BMI22.5 (2.6)), or any medical condition requiring
treatment were excluded. This study was approved by the
Oxford Research Ethics Committee (REC No: 11/SC/
0183) and by the Zurich ethics committee (KEK ZH 2010-
0054/1) and registered (NCT01130948).
Forty-seven obstructive sleep apnoea (OSA) patient
samples were used to examine samples with elevated
numbers of MVs. Patients were eligible if they were aged
between 45 and 75 years, and had proven OSA [mean
(SD) BMI33.4 (6.1)]. Fifty-eight per cent of the
OSA patients were on anti-hypertensives, 25% were on
cholesterol-lowering medication and 8% were on glucose-
lowering medication. The study was approved by the
Oxford Research Ethics Committee (REC No: 05/Q1604/
159). Written informed consent was obtained from all
participants.
For MV analysis, 2.7 ml of blood was drawn into
citrated vacutainer tubes containing 0.3 ml of 0.109M
(3.2%) buffered sodium citrate (Becton Dickinson, Oxford,
UK) using a 19G needle. The first blood tube was dis-
carded to avoid contamination with endothelial-derived
MVs generated during venepuncture. Tubes were centri-
fuged at 1,550 g for 20 min at 208C, to produce platelet-
poor plasma (PPP), within 15 min of the blood being
taken. PPP was carefully taken from the top of the tube,
without disturbing the buffy coat, frozen immediately
and stored at 808C for approximately 1 year prior to
analysis.
Flow cytometry analysis of MVs
Samples were analysed by flow cytometry as previously
described (15). Briefly, 250 ml of PPP was thawed at room
temperature. Samples were centrifuged twice at 18,000 g
for 30 min to pellet and wash the MVs. MVs were ulti-
mately re-suspended in 100 ml of PBS-citrate 0.32%.
Annexin V-fluorescein isothiocyanate (FITC) at 0.10
mg/ml and lactadherin-FITC at 1.38 mg/ml was used to
stain procoagulant MVs. CD31-phycoerythrin (PE, clone
WM59) at 0.10 mg/ml and CD41-phycoerythrin-Cy5 (PE-
Cy5, clone HIP8) at 0.013 mg/ml were used to differentiate
between platelet-derived MVs (PMVs, CD31CD41)
and endothelial-derived MVs (EMVs, CD31CD41-).
CD144-PE (clone 16B1) at 4.17 mg/ml, CD62E-PE-Cy5
(clone 68-5H11) at 0.42 mg/ml and CD106-PE-Cy5 (clone
51-10C9) at 0.21 mg/ml were also used as markers for
EMVs. Glycophorin-A (CD235a)-PE (clone GA-R2) at
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0.069 mg/ml was used to stain erythrocyte-derived MVs.
CD45-allophycocyanin (APC, clone 2D1) at 0.21 mg/ml
was used as a marker for total leucocyte-derived MVs
(LMVs). CD66B-FITC (clone G10F5) at 0.10 mg/ml was
used to stain granulocyte-derived MVs. CD14-PE (clone
M8P9) at 0.42 mg/ml was used to identify monocyte-
derived MVs. Annexin V-FITC and all antibodies were
supplied by BD (Oxford, UK), except for lactadherin
(HTI, Vermont, USA) and CD144 (eBioscience, Hatfield,
UK).
Samples were incubated with the appropriate mono-
clonal antibody for 30 min at room temperature, protected
from light, followed by the addition of 900 ml PBS-calcium
or 900 ml PBS-citrate in annexin control. Samples were
acquired using a BD FACSCalibur† (Becton Dickinson,
Oxford, UK). The positivity gates were checked by isotype
control and fluorescence minus one (FMO) staining.
Functional assay analysis of microparticles
Zymuphen MP ELISA
The Zymuphen ELISA (HYPHEN BioMed, Quadratech
Diagnostics, UK) is a functional assay that measures the
procoagulant activity of MVs in PPP. A microtitre plate is
pre-coated with annexin V-streptavidin. Phosphatidylser-
ine (PS) MVs bind to the plate and expose their
phospholipid surface, allowing the pro-thrombinase com-
plex to cleave prothrombin into thrombin. The phospho-
lipid in the sample is the limiting factor, so there is a direct
relationship between the MV phospholipid concentration
and the thrombin generation. Thrombin generation is
measured by a specific chromogenic substrate, giving an
indication of the phophatidylserine-expressing MV in the
sample (16).
The PPP samples and kit controls were diluted 1:20 in
the kit sample diluent, which is supplemented with cal-
cium, Factor Xa (FXa) and thrombin. A calibrator curve,
diluted controls and diluted samples were added to the
ELISA plate and incubated for 1 hour at 378C. The plate
was washed five times, then 100 ml of Reagent A (FXa
FVa) and 50 ml Reagent 2 (prothrombin) were added
and incubated for 10 min at 378C, then 50 ml of Reagent 3
(thrombin substrate) was added, and incubated for 3 min
at 378C. Finally, 50 ml of stop solution was added and the
plate was read at 405 nm, subtracting the blank. Results
were calculated from the calibrator curve and are ex-
pressed as nanomolar (nM) phophatidylserine equivalent.
STA† Phospholipid (PPL) Procoag Assay
STA† PPL Procoag assay (Stago, Berkshire, UK) mea-
sures the procoagulant activity of MVs by determining the
clotting time (16). The clotting time is dependent on the
procoagulant phospholipids of the sample. A shortened
clotting time indicates an increase in procoagulant phos-
pholipids (17), which is proportional to the procoagulant
MV level in the sample.
PPP samples were tested on the STA† automated ana-
lyser (Stago, Berkshire, UK), using the STA† Procoag-PPL
kit, according to the manufacturer instructions. Two
kit controls, with a known clotting time, were analysed
to check the reproducibility of the assay. Samples were
loaded and detection of procoagulant phospholipids was
automatically carried out. PPP was automatically diluted
with phospholipid-depleted plasma and incubated for
120 sec at 378C. The addition of reagents permits the
triggering of the coagulation cascade downstream from
FXa. The clot formation is dependent only on the pro-
coagulant phospholipids contained in the plasma sample.
A shortened clotting time indicates increased concen-
tration of phospholipids. The final result is expressed as
the clotting time in seconds.
Endogenous thrombin potential Assay
Thrombin generation can be assessed using a calibrated
automated thrombogram (Stago, Berkshire, UK). PRP
reagent containing 1 pM tissue factor (TF) and a minimal
amount of phospholipids (PRP reagent, TS42, Thrombi-
noscope BV) is added initially and acts as a trigger to
initiate thrombin generation. At fixed time intervals, a
sample is taken from the reaction and the amount of
thrombin generated is plotted to give a curve. When using
PPP, the thrombin generation is attributable to the pro-
coagulant MV concentration of that sample.
The endogenous thrombin potential (ETP) assay was
performed according to the manufacturer instructions.
PPP (80 ml) sample was added in duplicate to wells in
a 96-well plate. PRP reagent (20 ml; contains TF and
a minimal amount of phospholipids) was placed in one
set of wells and 20 ml thrombin calibrator was added to
the other set of wells. The thrombin calibrator corrects
for donor-to-donor differences in colour of plasma and
inner filter effects (18). The plate was warmed to 378C,
and then placed on the reader, a Fluoroskan Ascent
FL (Thermo Electron Corporation, Helsinki, Finland).
Fluca-Kit Reagent (20 ml), which causes the citrated
plasma to be re-calcified to start the reaction, was auto-
matically added to each well. The fluorescence inten-
sity was continuously measured by the Fluoroskan and
thrombin generation was plotted over 1 hour. The com-
puter software calculates lag time (min), the time to
peak (min), the peak of thrombin generation (nM) and
the area under the thrombin generation curve (nMmin)
or ETP.
Statistics
All statistics were performed using GraphPad Prism 5
Software (GraphPad Software, San Diego). The results
from each alternative MV assay were compared to the
results from the other assays and correlations were
determined by Spearman Correlation, due to the non-
parametric nature of the data. A p-value ofB0.05 was
considered statistically significant.
Microvesicle counts correlate with function
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Results
Samples
All 100 PPP samples were analysed by flow cytometry
and on the Zymuphen MP ELISA. Due to the required
sample volume requirement, 69 of the 100 samples could
be measured by the PPL assay and 78 of the 100 samples
were measured by the ETP assay.
Correlations between functional assays
In order to establish if the three functional assays were
giving similar results, correlation analysis was carried out.
Table I shows the Spearman r-values and the p-values
for correlations between the functional assays.
The ETP assay gives several readouts for the results,
including the ETP (nMmin) and the Peak (nM). As
expected, these two results were very closely positively
correlated (r0.9852, pB0.0001, Table I).
The results from the Zymuphen MP-ELISA were sig-
nificantly negatively correlated with the STA† PPL Pro-
coag (Fig. 1A) assay and positively associated with the
ETP and the Peak results from the ETP assay (Fig. 1B).
As expected the clotting times of the STA† PPL Pro-
coag assay were significantly negatively correlated with
the ETP and the Peak from the ETP assay (Fig. 1C).
Correlations between functional assays and
flow cytometry
In order to establish if the functional MV results from the
commercial assays were associated with the quantitative
results from the flow cytometry assay, correlation analysis
was carried out. Table II and Fig. 2 show the Spearman
r-values and the p-values for correlations between the
results from the functional assays and the results deter-
mined by flow cytometry.
The results from the Zymuphen ELISA were moder-
ately positively correlated with annexin V, lactadherin
and platelet-derived MVs as determined by flow cyto-
metry (Fig. 2A).
The results of the STA† PPL Procoag assay were
negatively correlated with annexin V, lactadherin
and platelet-derived MVs as measured by flow cytometry
(Fig. 2B).
The ETP and Peak results from the ETP assay were
positively correlated with annexin V, lactadherin 
and platelet-derived MVs results from the flow cytometry
assay (Fig. 2C).
None of the alternative assays were correlated with
any other microparticle subtype, including those derived
from endothelial cells, erythrocytes, leucocytes, granulo-
cytes or monocytes, as determined by flow cytometry
(data not shown).
Discussion
This study compared three functional assays to each other
and to the absolute counts of a broad range of MV sub-
types identified by flow cytometry in a large number
of samples from both healthy controls and patients,
allowing for comparisons to be drawn between several
assays, which measure different aspects of MVs functional
capacity. In general, results from the three functional
assays correlated well with each other. Procoagulant
MVs (as defined by annexin V and lactadherin) and
platelet-derived microparticles also correlate well with
these assays. As expected, MVs derived from other cells
were not correlated with the results from the functional
assays.
The Zymuphen MP ELISA was weakly positively
correlated with ETP and Peak from the ETP assay and
moderately negatively correlated with the STA† PPL
assay. The Zymuphen MP ELISA measures the procoa-
gulant surface and gives results in nM phophatidylserine
equivalent, the other functional assays give an indica-
tion of clotting and thrombin generation rate, possibly
explaining the weaker association. The Zymuphen MP
ELISA was only weakly positively correlated with pro-
coagulant MV absolute counts measured by flow cytome-
try and this association was not as strong as the other
two functional assays. These findings are supported by
Bohling et al. (19), who noted a moderate correlation
between platelet-derived MVs measured by flow cytome-
try and the results from a chromogenic assay. The weaker
association may be due to the phosphatidylserine con-
tribution of small MVs, which are measured by the
Zymuphen MP ELISA, but cannot be detected by flow
cytometry.
Table I. Correlations between functional assays
Zymuphen ELISA PPL Procoag assay ETP assay  ETP ETP assay  peak
Spearman r P Spearman r P Spearman r P Spearman r P
Zymuphen MP ELISA 0.5308 B0.0001 0.5498 B0.0001 0.5638 B0.0001
PPL Procoag assay 0.5308 B0.0001 0.7672 B0.0001 0.7244 B0.0001
ETP assay  ETP 0.5498 B0.0001 0.7672 B0.0001 0.9852 B0.0001
ETP assay  peak 0.5638 B0.0001 0.7244 B0.0001 0.9852 B0.0001
P-value and r-value from Spearman correlation. PPLphospholipid Procoag assay clotting time; ETPendogenous thrombin potential;
peakpeak thrombin generation.
Lisa Ayers et al.
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The STA† PPL Procoag assay was negatively corre-
lated with ETP and Peak results from the ETP assay and
moderately negatively correlated with the Zymuphen
ELISA results. A negative association would be expected,
as a shorter PPL clotting time indicates more procoagu-
lant phospholipids in the sample. This assay was also
significantly negatively correlated with procoagulant and
platelet-derived MVs, suggesting that quantitative results
Fig. 1. Correlations between the three functional assays.
APPL vs. Zymuphen; BETP vs. Zymuphen; CETP vs. PPL. P-value and r-value from Spearman correlation. PPLpho-
phospholipid Procoag assay clotting time; ETPendogenous thrombin potential; peakpeak thrombin generation; secseconds.
Table II. Correlations between functional assays and flow cytometry results
Zymuphen ELISA PPL Procoag assay ETP assay  ETP ETP assay  peak
Flow cytometry levels Spearman r P Spearman r P Spearman r P Spearman r P
Annexin V MVs 0.5207 B0.0001 0.7297 B0.0001 0.6427 B0.0001 0.6550 B0.0001
Lactadherin MVs 0.5370 B0.0001 0.7872 B0.0001 0.7444 B0.0001 0.7505 B0.0001
CD31CD41 PMVs 0.5203 B0.0001 0.8632 B0.0001 0.7268 B0.0001 0.7084 B0.0001
P-value and r-value from Spearman correlation. PPLphospholipid Procoag assay clotting time; ETPendogenous thrombin potential;
MVsmicrovesicles; PMVsplatelet microvesicles.
Microvesicle counts correlate with function
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from flow cytometry are related to the clotting potential
of MVs. This is supported by the data from two other
studies which also found strong negative correlations
between platelet-derived MVs detected by flow cytometry
and the results from the STA† PPL Procoag assay (19,20).
The ETP and Peak results were both positively
correlated with procoagulant and platelet-derived MVs.
Both ETP and Peak appear to give a good indication of
procoagulant MVs present in a sample, again indicating
that quantitative results from flow cytometry are related
to the functional capacity of MVs. This is supported by
the findings of a study on ageing, where an association
between annexin V MVs measured by flow cytometry
and the peak measured by thrombin generation was found
(21). A further study also reported a positive correlation
between platelet MV results from flow cytometry and
peak thrombin generation (20).
This study has shown that the STA† PPL Procoag
assay and the ETP assay correlate better with the absolute
counts from flow cytometry than the total phosphatidyl-
serine concentration of MVs. This may suggest that most
of the clotting and thrombin generation activity is present
in the large MVs, detected by flow cytometry, whereas
much of the phosphatidylserine exposure is accounted for
by smaller MVs.
Functional assays have been developed to detect
procoagulant MVs. As expected they correlate with each
other and with annexin V, lactadherin and platelet-
derived MVs. No significant correlations were found
between the functional assays and other MV subtypes,
which included those derived from endothelial cells,
erythrocytes, leucocytes, granulocytes or monocytes. En-
dothelial MVs have previously been found to be mainly
annexin V negative (22). Indeed we observed that a sig-
nificant proportion of MVs derived from endothelial
cells and leucocytes (in some cases 50%) do not bind
to annexin V or lactadherin, compared to over 90%
of platelet-derived MVs which bound annexin V and
lactadherin. Also, these vesicles only encompass a small
proportion of the total MV pool, being measured by the
functional assay, making them less likely to contribute to
the overall functional capacity.
Studies have shown that MVs bearing TF on their
surface possess the highest prothrombotic potential and
these MVs may be predictive of thrombosis in patients
with cancer (2325). Due to this potential clinical utility,
functional assays have been developed that specifically
measure TF bearing MVs. TF MVs were not investi-
gated in the current study due to the expected extremely
low levels being present in the populations examined.
Functional assays provide a quick and relatively cheap
method of screening large numbers of samples for pro-
coagulant MVs. They provide functional information
about the MVs and they can measure the contribution
of vesicles too small to be detected by flow cytometry.
However, they cannot give an absolute count of MVs and
they provide no information about the cellular origin. It
is likely that a range of assays is necessary to provide the
Fig. 2. (Continued).
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most comprehensive information about the quantitative
levels and functionality of circulating cell-derived MVs.
Interestingly all three functional assays and flow
cytometry show some discrimination between the healthy
control samples (Fig. 2; blue circles) and the samples
from OSA patients (red triangles). It should be noted that
the OSA patients in this study had significantly higher
BMIs than the healthy controls and some of the OSA
patients were on disease modifying medications (includ-
ing cholesterol lowering treatments) not used by the
healthy controls. These differences between the groups
may have contributed to the discrimination in MV levels.
However, several other studies have demonstrated that
procoagulant and platelet MVs are elevated in OSA
patients (26,27), and that MV levels are affected by
effective treatment of the disease (28,29).
Fig. 2. Correlations between functional assays and flow cytometry.
Aflow cytometry vs. Zymuphen; Bflow cytometry vs. PPL; Cflow cytometry vs. ETP. P-value and r-value from Spearman
correlation. PPLphospholipid Procoag assay clotting time; ETPendogenous thrombin potential; MVsmicrovesicles;
PMVsplatelet-derived microvesicles.
Microvesicle counts correlate with function
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Limitations
Correlations between the Zymuphen MP ELISA and the
flow cytometry results were examined in all 100 samples.
However, sample volume requirements meant that fewer
samples could be analysed by the STA† PPL Procoag
assay and the ETP assay. Ideally all 100 samples would
have been measured in all assays. Platelet-poor-plasma
was used to compare the assays, as opposed to platelet-
free plasma, therefore, some ex vivo generation of PMVs
may have occurred during the freezethaw process. Citrate
blood samples were used, not corn trypsin inhibitor
samples, so contact activation may contribute to the
thrombin generation assays. Samples were stored at
808C for approximately 1 year prior to analysis. Long-
term storage of samples at 808C can impact on the
absolute counts of MVs detected (15) and may have had
differential impacts on the functional assays. Despite these
limitations, we show good correlations between the four
assays examined.
Conclusions
The absolute counts of procoagulant and platelet-derived
MVs obtained from conventional flow cytometry correlate
with functional assay results, suggesting that the quanti-
tative results given by flow cytometry are associated with
the functional capability of the MVs, perhaps explain-
ing how conventional flow cytometry is able to generate
clinically relevant results. Functional assays are useful
in screening large populations for procoagulant MVs;
however, flow cytometry is still necessary for obtaining
information on other MV subtypes. Therefore, the com-
bination of several analytical techniques will give the
most comprehensive information of the role of MVs in
health and disease. Development of Fluorescent NTA and
dedicated flow cytometers for measuring all size ranges
of vesicles is required to phenotype the entire size range
of vesicles encountered in biological samples.
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